跳到正文
原文
Nature 健康护理主题·· 7 天前AI 评分43

Platelet-rich fibrin 在头颈部放疗患者拔牙窝的应用:系统综述

Platelet-rich fibrin in dental extraction sockets of patients with planned or previous head and neck radiotherapy: a systematic review

AI 导读

本系统综述评估了在计划或接受过头颈部放疗患者的拔牙窝中使用血小板浓缩纤维蛋白(PRF)的效果,旨在改善愈合结果或降低放射性颌骨坏死(ORN)风险。研究纳入了从数据库 inception 到 2025 年 12 月的文献,共检索到相关研究,但未发现符合纳入标准的随机对照试验或非随机对照试验。PRF 在非放疗拔牙窝中可减轻术后疼痛并加速软组织愈合,提示其在放疗前拔牙中的潜在益处。

正文

Introduction

Head and neck cancer (HNC) encompasses malignancies of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, and salivary glands and represents the seventh most common cancer globally [1]. Radiotherapy (RT) remains a common treatment modality for HNC. Despite advances in delivery technique, the proximity of the maxilla and mandible to RT target volumes can result in significant radiation-related oral morbidity [2,3,4]. Osteoradionecrosis (ORN) of the jaw is a serious late complication [5]. According to the Delanian–Lefaix fibroatrophic model [6, 7], RT-induced free radical generation triggers endothelial apoptosis and fibroblast-to-myofibroblast transformation. This results in a hypoxic, hypovascular, hypocellular tissue environment in which bone death exceeds repair capacity. Reported ORN incidence following post-RT dental extraction is approximately 10% [8], with the mandibular posterior region at doses exceeding 50–60 Gy at highest risk [8,9,10].

Patients diagnosed with HNC should undergo a pre-treatment restorative dental assessment to identify teeth of poor prognosis that require extraction before RT commences [11]. Extractions performed pre-RT carry lower ORN risk than those performed post-RT [12]. Current guidance recommends a minimum healing interval of 14–21 days between extraction and RT commencement [11]. Incomplete socket epithelialisation at RT commencement is an independent predictor of ORN [13, 14]; any intervention that accelerates socket healing within this narrow timeframe is therefore of clinical relevance.

Platelet-rich fibrin (PRF) is a second-generation autologous platelet concentrate introduced by Choukroun et al. [15]. Prepared by centrifugation of peripheral venous blood without anticoagulants, PRF yields a fibrin clot concentrated with platelets, leucocytes, and growth factors including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), and insulin-like growth factor-1 (IGF-1). A more recent variant of these included concentrated growth factors (CGF). These are released progressively as the fibrin matrix degrades, providing a sustained angiogenic and osteogenic stimulus [16]. In non-irradiated extraction sockets, PRF significantly reduces postoperative pain and accelerates soft tissue healing compared to conventional management [17, 18], suggesting a plausible mechanism for benefit in the pre-RT context.

The objective of this systematic review is to evaluate the clinical evidence for PRF placement in dental extraction sockets for patients with planned or prior head and neck RT, to critically appraise the methodology of available evidence, and to identify future research priorities.

Research question: Does PRF, when placed in extraction sockets, improve healing outcomes or reduce the risk for ORN in irradiated patients?

Methods

This review was conducted in accordance with the PRISMA 2020 statement (the completed PRISMA 2020 checklist is provided as Supplementary File 1). No protocol registration was completed prior to research initiation. The review protocol was not prospectively registered with PROSPERO or another registry; the rationale for, and implications of, the absence of prospective registration are addressed in the Limitations.

Search strategy

Electronic searches were conducted in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and the HaNDLE-on-QoL database (a dedicated repository of head and neck cancer quality-of-life literature) [19] from database inception to 31 December 2025. Searches were first run on 05/03/2026 and re-run on 29/05/2026; no additional eligible records were identified on re-running. No language restrictions were applied. The research was reviewed extensively to iteratively develop a research strategy. MeSH terms and free-text keywords included: ‘platelet-rich fibrin’, ‘PRF’, ‘L-PRF’, ‘A-PRF’, ‘CGF’, ‘platelet concentrate’, ‘dental extraction’, ‘tooth extraction’, ‘alveolar socket’, ‘radiotherapy’, ‘radiation therapy’, ‘head and neck cancer’, ‘osteoradionecrosis’, ‘ORN’, and ‘socket healing’. Within each concept block, terms were combined using the Boolean operator OR, and the three blocks were combined using AND, following the structure: (platelet concentrate terms) AND (dental extraction or socket terms) AND (radiotherapy, head and neck cancer or osteoradionecrosis terms). Database-specific controlled vocabulary (MeSH in PubMed/MEDLINE, Emtree in Embase) was mapped to each block and supplemented with free-text terms searched in title and abstract fields, with truncation applied where supported. Reference lists of included studies and relevant systematic reviews were hand-searched. Grey literature and conference abstracts were not searched, in order to restrict the synthesis to peer-reviewed and methodologically appraisable data; the implications of this for a niche evidence base are considered in the Limitations.

Eligibility criteria

The PICO framework is presented in Table 1. Eligibility criteria are detailed in Table 2. Studies reporting PRF use in extraction sockets of patients with confirmed HNC where radiotherapy was planned or already provided were eligible. Eligible study designs were restricted to primary clinical studies (randomised and non-randomised controlled trials, cohort, and case-control studies); previously published systematic reviews and meta-analyses were not included in the primary synthesis but were used for reference-list screening and as contextual evidence. Studies were required to report at least one pre-specified outcome. Animal studies, in vitro research, studies in non-oncological patients, case reports/series, and conference abstracts were excluded.

Table 1 PICO Framework.

Full size table

Table 2 Eligibility criteria.

Full size table

Data extraction and quality assessment

Two reviewers independently screened titles and abstracts using the Rayyan platform [20] with blinding, followed by full-text review. Discrepancies were resolved by consensus between the two reviewers. A third author was available to facilitate discussion if required. Data extracted included: study design, year, country, sample size, RT dose and modality, PRF variant and preparation protocol, comparator, co-interventions, follow-up duration, and outcomes. For each study the unit of randomisation and the unit of statistical analysis were recorded separately, together with the number of extraction sockets contributed per participant and whether the analysis made any allowance for clustering of multiple sockets within the same patient. Risk of bias in RCTs was assessed using the Cochrane Risk of Bias (RoB) 2.0 tool [21]. GRADE certainty ratings were assigned to pooled evidence where available from included systematic reviews [22]. The study selection process, including the numbers of records identified, screened, assessed for eligibility, and excluded with reasons, is summarised in the PRISMA 2020 flow diagram (Fig. 1). A risk-of-bias summary (traffic-light plot) for the two included RCTs, generated with the RoB 2.0 tool, is provided in Fig. 2. The systematic review retained as contextual evidence (Quah et al.) was not formally appraised using a dedicated critical-appraisal instrument (e.g. AMSTAR-2), as it did not form part of the primary synthesis; this is acknowledged as a limitation.

Fig. 1: PRISMA flow diagram.

RT radiotherapy, ORN osteoradionecrosis, PRF platelet-rich fibrin. The systematic review did not meet the eligibility criteria for a primary study and was retained solely for context.

Fig. 2

Risk-of-bias summary (traffic-light plot) for the two included randomised controlled trials, assessed with the Cochrane RoB 2.0 tool across the five domains (D1–D5) and overall.

Ethical approval

This study did not involve human participants and represents a review of existing publications. Consequently, a human ethics application is not applicable. The accepted standards as outlined by the Declaration of Helsinki were upheld. Ethical approval was not required.

Results

Study selection

The search identified 155 records (PubMed/MEDLINE n = 62, Embase n = 41, Web of Science n = 29, Cochrane Central Register of Controlled Trials n = 23, HaNDLE-on-QoL n = 0); eight duplicates were removed. After screening titles and abstracts (n = 147), 23 full texts were assessed for eligibility. Two primary studies, both RCTs, were included in the qualitative synthesis (Fig. 1); one systematic review with meta-analysis (Quah et al.) was retained separately as contextual evidence and was not included in the primary synthesis. The two categories are reported separately throughout and are distinguished in Fig. 1: only the two RCTs met the eligibility criteria and contributed to the qualitative synthesis, whereas the systematic review did not meet those criteria as a primary study and was retained solely to contextualise the findings. No study examined PRF use specifically in the pre-RT extraction socket context.

Included studies

Palma et al. [22] conducted an RCT in 23 irradiated HNC patients randomised to L-PRF (n = 11) or conventional management controls (n = 12), all of whom had received conventionally fractionated three-dimensional conformal radiotherapy to a total dose of 60–70 Gy. Eligibility was restricted to patients requiring a single tooth extraction, so each participant contributed one socket to the study. The patient was therefore both the unit of randomisation and the unit of analysis. All participants received perioperative antibiotics (clindamycin 300 mg eight-hourly for 10 days, commencing three days pre-operatively) alongside an atraumatic surgical protocol. L-PRF was prepared from a 20 mL peripheral venous sample collected into two vacuum tubes containing clot activator and centrifuged at approximately 400 g for 12 minutes (Daiki DT-4000, Ionlab, Brazil); two clots were produced per patient, one chopped to fill the socket and one compressed to cover it, retained with an X suture. No case of ORN, and no other postoperative complication, occurred in either arm within the 180-day follow-up (0/11 versus 0/12). A single participant, in the L-PRF arm, reported postoperative pain (visual analogue score 2 on day 3), with no significant difference between arms at day 3 or day 7 (p = 0.307). The trial used a convenience sample, and no a priori sample size calculation was reported.

Macedo et al. [23] reported a double-blind, split-mouth RCT in 30 post-irradiated HNC patients (radiation dose > 50 Gy; most commonly 70.2 Gy) contributing 134 extraction sockets. The socket, rather than the patient, was the unit of randomisation. Sockets were allocated to A-PRF (n = 67) or clot maintenance alone (n = 67), with each participant contributing sockets to both arms (a mean of approximately 4.5 sockets per patient). The authors state that, for statistical purposes, each post-exodontia socket was considered an individual case. Clustering was accounted for only in part: a linear mixed model was applied to the continuous healing index. Wound closure, bone exposure, ORN and oedema were compared using Fisher’s exact test, which treats sockets as independent. A-PRF was prepared from two additive-free 9 mL glass tubes (18 mL total) centrifuged at 1300 rpm (208 g) for 14 minutes (Duo Quattro, Process for PRF, Nice, France), with a single clot placed per socket. All patients received amoxicillin 500 mg eight-hourly from three days pre-operatively and for seven days postoperatively. The sample size was calculated for degree of complete epithelialisation rather than for ORN, and 30 of the 32 patients indicated by that calculation were enrolled. Clinical evaluation was undertaken at 7, 14, 30, 60, 90 and 120 days. No case of ORN was recorded in either arm at 90 or 120 days (0/67 versus 0/67), and median pain scores were zero in both arms at every time point. Complete wound closure was, however, more frequent in the control arm than in the A-PRF arm at 7 days (58/67, 86.5% versus 49/67, 73.1%; unadjusted risk difference −13.4%, 95% CI−26.6% to 0.2%) and at 14 days (57/67, 85.0% versus 47/67, 70.1%; unadjusted risk difference −14.9%, 95% CI−28.5% to −0.7%), reported by the authors as statistically significant.

As contextual evidence, Quah et al. [24] conducted a systematic review and meta-analysis of five adjunctive modalities in post-radiotherapy extraction sites across 29 studies (n = 1520 patients). Only one PRF study was considered eligible. This study recruited 11 participants, with an ORN prevalence of 0%. Pooled ORN rates for the other groups were: hyperbaric oxygen (HBO) 4.6%, pentoxifylline-tocopherol (PENTO) 3.4%, and antibiotics 3.8%, compared with 17.6% in untreated controls. GRADE certainty of evidence for PRF was rated ‘very low’.

A summary of the included studies is presented in Table 3.

Table 3 Summary of Included Studies.

Full size table

Discussion

The existing evidence is structurally unable to answer the clinical question in its current form. The absence of a statistically significant finding in both RCTs should not be interpreted as evidence that PRF is ineffective; rather, it indicates that the trials lacked the power to detect a clinically meaningful effect had one been present. Assuming the accepted prevalence of ORN [8, 10, 25, 26] and a hypothesised 50% relative risk reduction [18], a two-arm RCT requires approximately 425 patients per arm (assuming a control-arm ORN incidence of 10%, two-sided α = 0.05 and 80% power) to be adequately powered. Palma et al. [22] enrolled 11 patients in the PRF arm; and Macedo et al. [23] enrolled 67 sockets (not independent patients). Both trials were therefore operating at a statistical power of approximately 5–10% for this outcome. Failure to detect a benefit under such conditions places these trials at high risk of a type II error. Neither trial was designed to test ORN as an outcome (due to the method in which sample size was calculated). Palma et al. used a convenience sample with no a priori power calculation, and Macedo et al. calculated their sample size for degree of epithelialisation rather than for ORN. The assumed 50% relative risk reduction is, however, an optimistic extrapolation: it is derived from a meta-analysis of PRF in soft-tissue healing and recovery after third molar surgery in non-irradiated patients [18], and no equivalent effect has been demonstrated for ORN, which is a bone pathology mechanistically distinct from soft-tissue socket healing. The required sample size is highly sensitive to this assumption: holding the baseline ORN incidence at 10% (two-sided α = 0.05, 80% power), a 50% relative risk reduction requires approximately 425 patients per arm, a 40% reduction approximately 715 per arm, and a 30% reduction approximately 1350 per arm. The estimate of ‘5–10% power’ for the existing trials should accordingly be read as an order-of-magnitude figure under these stated assumptions rather than a precise value.

While the results provide valuable insights, they should be tempered by several inherent methodological constraints. Osteoradionecrosis (ORN) takes significant time to develop. Consequently, there is a natural scarcity of published research. The small number of available papers limits the ability to generalise these findings across broader populations.

The most clinically relevant finding of this review is the complete absence of studies in the pre-RT context. In the “pre-RT socket”, tissue vascularity is intact and the wound healing cascade is unimpaired. The biological case for PRF is stronger here than in post-RT tissue, where Delanian and Lefaix [7] demonstrated that RT-induced fibroatrophy produces progressive endothelial dysfunction. Haimovitz-Friedman et al. [27] showed that ionising radiation alters growth factor gene expression in endothelial cells in a dose- and time-dependent manner, including the PDGF and bFGF signalling axes through which PRF exerts its principal angiogenic effects. In the post-RT microenvironment, therefore, the cellular mechanism on which PRF depends may itself be compromised. As such, the two existing RCTs have evaluated PRF in the post-RT setting, where it is least likely to impart a biological benefit.

Incomplete socket epithelialisation at RT commencement is associated with an increased risk of ORN [13]. Systematic review evidence demonstrates that PRF significantly accelerates soft tissue closure in non-irradiated extraction sockets at 7- and 14-days post-extraction [17, 18]. If this benefit is reproducible in the pre-RT population, even a modest reduction in the healing interval could have a substantial clinical impact on the risk of ORN. This hypothesis is biologically coherent, clinically important, and untested in clinical trials. A distinction should be drawn between biological plausibility and demonstrated clinical effectiveness. No clinical study has evaluated PRF in a pre-RT extraction socket, and no claim about its effectiveness in that setting can currently be supported by direct evidence.

Three interacting methodological problems undermine the available RCTs beyond sample size alone.

First, universal antibiotic co-intervention constrains interpretability, though not through confounding in the conventional sense. Quah et al. [25] reported that antibiotics alone reduce ORN from 17.6% to 3.8%: a 78% relative risk reduction. Because antibiotics were administered to every participant in both arms of both trials, they cannot have generated a systematic difference between the groups and are not, strictly, a confounder of the treatment comparison. Their influence is instead on the baseline event rate. By suppressing the incidence of ORN in the control condition towards zero, they leave little residual risk for PRF to reduce, so that any additional effect of PRF becomes correspondingly more difficult to detect at the sample sizes studied. The observed outcome (no case of ORN in either arm of either trial) is consistent with this interpretation. A further areas for consideration is L-PRF has itself been shown to act as a local reservoir for antibiotic release, so the two interventions may not be wholly independent of one another [28].

Second, the follow-up duration was inadequate to assess most ORN events. Balermpas et al. [29] reported a median time to ORN onset of 12.8 months in intensity-modulated radiotherapy (IMRT)-treated cohorts, with substantial proportions presenting beyond 24 months. Both RCTs used a 120–180-day follow-up. Their ORN event rates would therefore be systematically underestimated, further increasing the risk of false negatives.

Third, PRF product heterogeneity invalidates cross-study comparisons. Dohan Ehrenfest et al. [30] established that centrifugation conditions are the primary determinant of PRF composition, with up to five-fold variation in PDGF-AB and TGF-β1 content between L-PRF (400 g) and A-PRF (200 g) protocols [31]. Both RCTs did in fact report relative centrifugal force: approximately 400 g for 12 minutes in Palma et al. and 208 g (1300 rpm) for 14 minutes in Macedo et al. (the standardised parameter recommended by Ghanaati et al. [32]). The difficulty is therefore not one of reporting but of comparability. The two protocols differ approximately two-fold in RCF and also in spin duration, tube type, blood volume and the number of clots placed per socket, and were performed on different centrifuges. On the data of Dohan Ehrenfest et al. and Miron et al., differences of this magnitude would be expected to yield materially different growth factor content, so the two trials cannot be assumed to have tested the same biological product. Pooling them without accounting for this heterogeneity would be methodologically questionable, and future trials should report RCF, spin time, rotor geometry, blood volume and clot number in full.

The 0% ORN rate in the single PRF study identified by Quah et al. [25] compares numerically favourably with pooled rates for HBO (4.6%), PENTO (3.4%), and antibiotics (3.8%). However, this result is based on only 11 patients and carries a GRADE certainty of ‘very low’. It would therefore be inappropriate to use this figure to position PRF above better-studied modalities.

A randomised controlled clinical trial investigating the effectiveness of PRF in reducing the prevalence of ORN in pre-RT extraction sites would be of clear value, although feasible only as a multicentre collaboration given the sample size required. Minimum design requirements are proposed in Appendix 1. Key features include: prospective enrolment of pre-RT patients; a sample size of at least 850 (approximately 425 per arm) based on a 10% baseline ORN rate and a hypothesised 50% relative risk reduction; standardised A-PRF preparation protocol (RCF-reported [33]); primary endpoint of ORN at 24 months; and prospective trial registration with a pre-specified statistical analysis plan.

The absence of evidence of benefit is not evidence of harm, but neither does it constitute grounds for recommending use. PRF is autologous, has no reported systemic adverse effects and imposes a modest procedural burden; set against this, the only comparative data available in irradiated patients show no benefit, and in one trial showed less complete wound closure in the PRF arm at 7 and 14 days. Given the quantity and quality of the available evidence, PRF cannot be recommended for routine use and any use should be regarded as investigational. Where a clinician nonetheless elects to use it, it should be strictly as an adjunct to, and never a substitute for, established preventive measures (atraumatic technique, primary closure, adjunctive antibiotics, and adequate healing time before RT). It has been suggested that use might reasonably be prioritised in patients at highest risk, and it should be emphasised that this proposition rests on biological reasoning alone. It is also in precisely these highest-risk patients that an ineffective adjunct carries the greatest opportunity cost, should it displace or delay measures of established value. Informed consent should state explicitly that no clinical trial evidence of benefit exists in this setting.

Limitations

This review has several limitations. First, the review protocol was not prospectively registered, for example with PROSPERO. Prospective registration is increasingly expected for systematic reviews, and its absence raises the possibility of publication or selective-reporting bias and reduces transparency regarding any deviation from a pre-specified plan. Registration was not undertaken because the review addressed a deliberately narrow question for which the eligible primary literature was known to be very small; to mitigate the associated risks, eligibility criteria were defined a priori, study screening and data extraction were performed independently in duplicate, and reporting follows the PRISMA 2020 statement (Supplementary File 1).

Second, grey literature and conference abstracts were not searched. In a niche field, this may have excluded relevant pilot data or ongoing work; notably, at least one trial of PRF applied before radiotherapy is registered and ongoing (ClinicalTrials.gov NCT06406530), indicating that direct evidence for the pre-RT setting may emerge in the coming years.

Third, only two small primary studies were eligible, both performed after radiotherapy; this limits the generalisability of any synthesis and precluded meta-analysis. The systematic review by Quah et al. was used only as contextual evidence and was not formally appraised with a critical-appraisal instrument such as AMSTAR-2, and this should be borne in mind when interpreting the pooled figures it reports. Finally, heterogeneity in PRF preparation, comparator regimens, universal antibiotic co-intervention and follow-up duration across the available studies constrains direct comparison and represents an important potential source of bias, as discussed above.

Conclusions

PRF is biologically plausible as an adjunct in pre-RT dental extraction sockets, but biological plausibility is not clinical effectiveness, and no direct evidence of benefit exists in that setting. The existing clinical evidence, derived solely from post-irradiated patients in two substantially underpowered RCTs at high risk of type II error, is insufficient either to support or to refute its routine use. The pre-RT setting remains uninvestigated, and no direct clinical evidence currently exists for this setting. Well-designed, adequately powered, multicentre RCTs enrolling pre-RT HNC patients are a research priority. Until such evidence is available, PRF should be considered investigational, should not be presented to patients or colleagues as an established means of reducing ORN risk, and where used should be used only as an adjunct to established preventive strategies, with its application documented so as to contribute to the real-world evidence base.

References

  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

    PubMed  Google Scholar 

  2. Wissinger E, Griebsch I, Lungershausen J, Foster T, Pashos CL. The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics. 2014;32:865–82.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ho KF, Farnell DJJ, Routledge JA, Burns MP, Sykes AJ, Slevin NJ, et al. Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy. Radiother Oncol. 2010;97:270–5.

    Article  PubMed  Google Scholar 

  4. Rogers SN, Monssen C, Humphris GM, Lowe D, Kanatas A. Which head and neck cancer patients are most at risk of high levels of fear of cancer recurrence. Front Psychol [Internet]. 2021;12. Available from: https://pubmed.ncbi.nlm.nih.gov/34335384/,

  5. Safdar Y, Amin I, Kanatas A. A novel approach to the management of Osteoradionecrosis – The Leeds Way. Int J Oral Maxillofac Surg. 2025;54:125–6.

    Article  Google Scholar 

  6. Peterson DE, Koyfman SA, Yarom N, Lynggaard CD, Ismaila N, Forner LE, et al. Prevention and management of Osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO-MASCC-ASCO Guideline. J Clin Oncol. 2024;42:1975–96.

    Article  CAS  PubMed  Google Scholar 

  7. Delanian L. The radiation-induced fibroatrophic process: Therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004;73:119–31. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39470150%0A10.1016/j.radonc.2004.08.021.

    Article  PubMed  Google Scholar 

  8. Shaw RJ, Butterworth CJ, Silcocks P, Tesfaye BT, Bickerstaff M, Jackson R, et al. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A randomized controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible after dentoalveolar surgery. Int J Radiat Oncol Biol Phys. 2019;104:530–9. https://doi.org/10.1016/j.ijrobp.2019.02.044.

    Article  PubMed  Google Scholar 

  9. Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg, Oral Med Oral Pathol. 1987;64:379–90.

    Article  CAS  PubMed  Google Scholar 

  10. Pereira I, Firmino R, Meira H, Vasconcelos B, Noronha V, Santos V Osteoradionecrosis prevalence and associated factors: A ten-year retrospective study. Med Oral Patol Oral y Cir Bucal [Internet]. 2018;0–0. Available from: http://www.medicinaoral.com/medoralfree01/aop/22310.pdf.

  11. Butterworth C, McCaul L, Barclay C. Restorative dentistry and oral rehabilitation: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol [Internet]. 2016;130:S41–4. http://www.journals.cambridge.org/abstract_S0022215116000414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. El-Rabbany M, Duchnay M, Raziee HR, Zych M, Tenenbaum H, Shah PS, et al. Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy. Cochrane Database Syst Rev. 2019;2019.

  13. Jham BC, Freire ARDS. Oral complications of radiotherapy in the head and neck. Braz J Otorhinolaryngol. 2006;72:704–8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Corrao G, Mazzola GC, Lombardi N, Marvaso G, Pispero A, Baruzzi E, et al. Oral surgery and osteoradionecrosis in patients undergoing head and neck radiation therapy: an update of the current literature. Biomedicines. 2023;11:3339. Available from: https://www.mdpi.com/2227-9059/11/12/3339.

  15. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution. Oral Surgery. Oral Med Oral Pathol Oral Radio Endodontol. 2006;101:e37–44. https://linkinghub.elsevier.com/retrieve/pii/S107921040500586X.

    Article  Google Scholar 

  16. Jia K, You J, Zhu Y, Li M, Chen S, Ren S, et al. Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization. Front Bioeng Biotechnol. 2024;12.

  17. Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Investig [Internet]. 2017;21:1913–27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28551729.

  18. Ye L, He Y, Ma W, Zhou F, Liu J. Effect of platelet-rich fibrin on the recovery after third molar surgery: A systematic review and meta-analysis. J Cranio-Maxillofac Surg. 2024;52:1095–108.

    Article  Google Scholar 

  19. Rogers, LK. HaNDLE-on-QoL: Head and Neck Database Listing Evidence on Quality of Life [Internet]. [cited 2026 May 29]. Available from: http://www.handle-on-qol.com.

  20. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan- a web and mobile app for systematic reviews. Syst Rev. 2016;5.

  21. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:4898.

    Article  Google Scholar 

  22. GRADE Working Group [Internet]. 2026. Available from: https://www.gradeworkinggroup.org/.

  23. Palma LF, Marcucci M, Remondes CM, Chambrone L. Leukocyte-and platelet-rich fibrin does not provide any additional benefit for tooth extraction in head and neck cancer patients post-radiotherapy: A randomized clinical trial. Med Oral Patol Oral y Cir Bucal. 2020;25:e799–804.

    Article  Google Scholar 

  24. Macedo DR, Rodrigues JF, de Paulo LFB, de Oliveira GJPL, Soares PBF. Effectiveness of advanced platelet-rich fibrin on post-exodontia socket healing in patients who had undergone head and neck radiation. Support Care Cancer. 2025;33.

  25. Quah, Y, Lai, I. Efficacy of adjunctive modalities during tooth extraction for the prevention of osteoradionecrosis: A systematic review and meta-analysis. Oral Dis [Internet]. 2024;30:3732–44. Available from: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1601-0825%0A, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2028660133.

  26. Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: A systematic review. Int J Oral Maxillofac Surg. 2011;40:229–43.

    Article  CAS  PubMed  Google Scholar 

  27. Haimovitz-Friedman A, Witte L, Chaudhuri A, McLoughlin M, Fuks Z. Induction of growth factor genes in endothelial cells by ionizing radiation. Radiat Oncol Investig. 1995;3:1–8.

    Article  CAS  Google Scholar 

  28. Peck M, Hiss D, Stephen L, Maboza E. Antibiotic release from leukocyte-and platelet-rich fibrin (L-PRF) -an observational study. South Afr Dent J. 2018;73:268–70.

    Google Scholar 

  29. Balermpas P, van Timmeren JE, Knierim DJ, Guckenberger M, Ciernik IF. Dental extraction, intensity-modulated radiotherapy of head and neck cancer, and osteoradionecrosis. Strahlenther Onkol. 2022;198:219–28. https://link.springer.com/10.1007/s00066-021-01896-w.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158–67.

    Article  CAS  PubMed  Google Scholar 

  31. Miron RJ, Fujioka-Kobayashi M, Sculean A, Zhang Y. Optimization of platelet-rich fibrin. Periodontol 2000. 2024;94:79–91. Feb.

    Article  PubMed  Google Scholar 

  32. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: A new concept for cell- Based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679–89.

    Article  PubMed  Google Scholar 

  33. Ghanaati S, Herrera-Vizcaino C, Al-Maawi S, Lorenz J, Miron RJ, Nelson K, et al. Fifteen years of platelet rich fibrin in dentistry and oromaxillofacial surgery: How high is the level of scientific evidence? J Oral Implantol. 2018;44:471–92.

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Restorative Dentistry, Leeds Teaching Hospitals Trust, Leeds, UK

    Jaymit Patel

  2. Leeds Community Healthcare NHS Trust, Leeds, UK

    Clare Granger

  3. Department of Oral Surgery & Oral and Maxillofacial Surgery, Queen Mary University of London & Barts Health Trust, London, UK

    Eleni Besi

  4. Department of Oral and Maxillofacial Surgery, Leeds Teaching Hospitals Trust, Leeds, UK

    Anastasios Kanatas

Authors

  1. Jaymit Patel
  2. Clare Granger
  3. Eleni Besi
  4. Anastasios Kanatas

Corresponding author

Correspondence to Jaymit Patel.

Ethics declarations

Competing interests

The authors declare no competing interests.

Consent to participate declaration

Not applicable (not human participants).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendix

Appendix 1 Proposed minimum design criteria for a definitive RCT

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, J., Granger, C., Besi, E. et al. Platelet-rich fibrin in dental extraction sockets of patients with planned or previous head and neck radiotherapy: a systematic review. BDJ Open 12, 113 (2026). https://doi.org/10.1038/s41405-026-00491-4

Download citation

  • Received: 06 July 2026

  • Revised: 21 August 2026

  • Accepted: 27 August 2026

  • Published: 13 November 2026

  • Version of record: 13 November 2026

  • DOI: https://doi.org/10.1038/s41405-026-00491-4

来源:Nature 健康护理主题 · nature.com